Blog Archives

SEMA4D gene variant quadruples obesity risk in individuals of African descent

March 26, 2017 – There is ample evidence that the burden of obesity is not the same across ethnic groups. While diet and lifestyle play a large role in determining body weight, there is also a heritable component. Unfortunately,  most prior studies that have evaluated the role of genes in obesity have looked mostly at people of European or Asian descent,

Read more ›

Tags: , , , , , , , , ,

If you are obese, can you blame it on your genes?

February 13, 2017 – If you are obese (or plain out fat), can you blame it on your genes? Actually, in very many cases, the answer is a qualified yes. Or a maybe. Under certain circumstances. Researchers are moving towards a better understanding of some of the roots of obesity.

Read more ›

Tags: , , , , , ,

Association of Psoriasis With the Risk for Type 2 Diabetes Mellitus and Obesity

Lønnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF

JAMA Dermatol 2016 Apr;

PMID: 27120802

Abstract

Importance: Psoriasis has been shown to be associated with overweight and type 2 diabetes mellitus. The genetic association is unclear.

Read more ›

Tags: , , , ,

The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA

December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension,

Read more ›

Tags: , , , , , , , , , , , ,

Weight-management drug Contrave approved

September 13, 2014 – The U.S. Food and Drug Administration approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

Body Mass Index 30The drug is approved for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as high blood pressure (hypertension),

Read more ›

Tags: , , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: chat

You must be a registered user to participate in this chat.

thasso: tweets

thasso: categories

thasso: archives

Top